Page last updated: 2024-09-04

vatalanib and gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate

vatalanib has been researched along with gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate in 2 studies

Compound Research Comparison

Studies (vatalanib)	Trials (vatalanib)	Recent Studies (post-2010) (vatalanib)	Studies (gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate)	Trials (gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate)	Recent Studies (post-2010) (gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate)
276	42	98	638	31	243

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Allegrini, PR; Drevs, J; Esser, N; Fuxius, S; Hennig, J; Hugenschmidt, H; Konerding, MA; Marmé, D; Müller-Driver, R; Unger, C; Wittig, C; Wood, J	1
Allegrini, PR; Baumann, D; Becquet, M; Brecht, K; Brueggen, J; Ferretti, S; McSheehy, PM; Rausch, M; Rudin, M; Schaeffer, F; Schnell, C; Wood, J	1

Other Studies

2 other study(ies) available for vatalanib and gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate

Article	Year
PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer research, 2002, Jul-15, Volume: 62, Issue:14 Topics: Angiogenesis Inhibitors; Animals; Benzimidazoles; Blood Vessels; Capillary Permeability; Carcinoma, Renal Cell; Enzyme Inhibitors; Extravasation of Diagnostic and Therapeutic Materials; Female; Fluorescent Dyes; Heterocyclic Compounds; Kidney Neoplasms; Magnetic Resonance Angiography; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Organometallic Compounds; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Regional Blood Flow	2002
PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo. NMR in biomedicine, 2005, Volume: 18, Issue:5 Topics: Animals; Cell Line, Tumor; Cell Proliferation; Contrast Media; Female; Heterocyclic Compounds; Magnetic Resonance Imaging; Melanoma; Metabolic Clearance Rate; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Organometallic Compounds; Phthalazines; Protein-Tyrosine Kinases; Pyridines; Vascular Endothelial Growth Factor A	2005

Article

Year

PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.

Cancer research, 2002, Jul-15, Volume: 62, Issue:14

Topics: Angiogenesis Inhibitors; Animals; Benzimidazoles; Blood Vessels; Capillary Permeability; Carcinoma, Renal Cell; Enzyme Inhibitors; Extravasation of Diagnostic and Therapeutic Materials; Female; Fluorescent Dyes; Heterocyclic Compounds; Kidney Neoplasms; Magnetic Resonance Angiography; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Organometallic Compounds; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Regional Blood Flow

2002

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.

NMR in biomedicine, 2005, Volume: 18, Issue:5

Topics: Animals; Cell Line, Tumor; Cell Proliferation; Contrast Media; Female; Heterocyclic Compounds; Magnetic Resonance Imaging; Melanoma; Metabolic Clearance Rate; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Organometallic Compounds; Phthalazines; Protein-Tyrosine Kinases; Pyridines; Vascular Endothelial Growth Factor A

2005